Instem, a leading provider of IT solutions and services to the global life sciences market, announced that it has further enhanced its Predict™ In Silico Toxicology service portfolio by adding four new services.
Also Read: iOnctura to Share Clinical and Preclinical Data on IOA-244 and IOA-289 at ESMO-IO in December
Predict™ is a leading edge, technology-enabled service that delivers a combination of powerful computation models with expert scientific review, to help clients predict chemical safety more quickly, efficiently, and comprehensively. Since its successful launch in December 2020, Instem has seen strong interest in the Predict™ service from clients across the globe.
These latest service offerings have been developed to address new regulatory guidance and will deliver further efficiencies and increased regulatory
New service highlights:
Establishing Acceptable Limits for N-nitrosamines – to support recent guidance from US FDA, EMA, and other regulatory authorities regarding the assessment and control of N-nitrosamine impurities and degradants.
Assessment of Abuse Liability – provides an in silico assessment of abuse liability for CNS-active substances to support their assessment in early discovery, the development of a testing strategy for abuse liability, and to answer regulatory questions.
Assessing Bioactivation – supports FDA guidance regarding the assessment of structural alerts for metabolites associated with mechanism-based inhibition (MBI). The service will generate and report the results of an in silico profile for MBI potential, including an expert review, and can also support the assessments of potential liver toxicity attributable to bioactivation.
SD File Generation – The US FDA recommends that pharmaceutical companies submit an electronic format (SD File) for chemicals included in their regulatory submissions (including impurities). This Predict™ service offering will process the molecules, validate, and create an SD file.
Dr. Glenn Myatt, Instem’s Vice President of Informatics said, “We have been delighted to see such high demand for our Predict services from existing and prospective clients alike and are pleased to add these new offerings to our portfolio.” Dr. Myatt continued “As the demand for reliable alternatives to traditional testing methods continues to grow, organizations of all sizes are recognizing the benefits that our Predict™ service can deliver.